Sensitive and rapid quantitation of dexamethasone in human plasma using liquid chromatography coupled with triple quadrupole mass spectrometer-Reference-Cited by-同舟云学术

Sensitive and rapid quantitation of dexamethasone in human plasma using liquid chromatography coupled with triple quadrupole mass spectrometer

Published:2023-08 Issue:4 Volume:29 Page:240-247
ISSN:1469-0667
Container-title:European Journal of Mass Spectrometry
language:en
Short-container-title:Eur J Mass Spectrom (Chichester)

Author:

Dubey Naveen Kumar¹^ORCID,Jain Peeyush¹

Affiliation:

1. Bioanalytical Department, Jubilant Generics Limited, Noida, India

Abstract

The aim of this paper was to develop, validate, and utilize a sensitive liquid chromatography-tandem mass spectrometry bioanalytical method for bioequivalence/clinical trial studies conducted in human plasma. To accomplish the target, a stable labeled internal standard, that is, dexamethasone D4was used as an internal standard to track and compensate the parent compound during processing, and extraction from plasma. The method involves a rapid liquid–liquid phase extraction from plasma, followed by reverse phase chromatography, and mass spectrometry detection, with a total run time of 3.5 min. The method was developed and validated from 2 to 600 ng/ml for dexamethasone. The mean recovery for dexamethasone was found to be 81.0%. The validated method enabled the analysis of dexamethasone in samples from clinical pharmacokinetic studies. The peak concentration of dexamethasone ranged between 253 to 281 ng/ml and 319 to 343 ng/ml, respectively, in fasted and fed conditions. The terminal half-life values for dexamethasone ranged between 3.5 to 8.2 h and 3.0 to 7.5 h, respectively.

Publisher

SAGE Publications

Subject

Spectroscopy,Atomic and Molecular Physics, and Optics,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/14690667231194812

Reference23 articles.

1. Dexamethasone and its properties. https://en.wikipedia.org/wiki/Dexamethasone (accessed 11 June 2022).

2. EMA-Dexamethasone Alapis Assessment report. 2011. https://www.ema.europa.eu/en/documents/referral/dexamethasone-alapis-article-29-referral-assessment-report_en.pdf (accessed on 18 May 2022).

3. New Drug Application-NDA-11-664/S-062. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/11664slr062_decadron_lbl.pdf (accessed on 18 May 2022).

4. Center for drug evaluation and research, application number: 211379Orig1s000, clinical pharmacology and biopharmaceutics review(S). 2019. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211379Orig1s000ClinPharmR.pdf (accessed on 19 May 2022)